Pfizer vs Merck
Two large-cap pharma leaders compared on patent-moat durability, pipeline risk, and margin of safety — a value look at drug-patent cliffs.
| Metric | PFIZER INC PFE | Merck & Co., Inc. MRK |
|---|---|---|
| ValueOS Score | 70 | 77 |
| Verdict | HOLD | HOLD |
| Moat | Narrow Moat | Narrow Moat |
| Margin of Safety | -113.2% | -154.1% |
| Intrinsic Value / share | $14.00 | $58.99 |
| Price | $29.85 | $149.88 |
Live scores from the latest SEC filings · refreshed daily. Open any card for the full workup.
The Takeaway
Merck leans on Keytruda and a deeper pipeline; Pfizer is more diverse but more exposed to patent cliffs. Both are wide-moat franchises — compare the Scores and margins of safety above to judge which is the better bargain at today's price.
Frequently Asked Questions
How do Pfizer and Merck differ as moats?
Merck's durability rests on Keytruda and a thicker pipeline; Pfizer's is broader but faces nearer patent expirations. Their moats come from different sources.
Which is better value today?
The DCF and Score cards above show intrinsic value, margin of safety, and business quality for each. Weigh durability against current price.
Run the full workup yourself
Open either name across the three tools for the complete Buffett-style analysis.
Cite this page
Quoting or linking ValueOS? Copy this ready-made citation.
ValueOS Editorial Team. "Pfizer vs Merck." ValueOS. Accessed 2026-10-22. https://getvalueos.com/compare/pfe-vs-mrk